Paragon Capital Management (Utah)’s Royalty Pharma RPRX Stock Holding History

Paragon Capital Management (Utah)’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-44,254	Closed	-$1.71M	–	85
2025 Q4	$1.71M	Sell	44,254 -5,033	-10%	-$192K	1.32%	21
2025 Q3	$1.74M	Sell	49,287 -2,120	-4%	-$76.7K	1.3%	25
2025 Q2	$1.85M	Sell	51,407 -902	-2%	-$29.9K	1.41%	18
2025 Q1	$1.63M	Sell	52,309 -18,030	-26%	-$571K	1.32%	18
2024 Q4	$1.79M	Buy	70,339 +53,937	+329%	+$1.43M	1.4%	18
2024 Q3	$464K	Sell	16,402 -49,241	-75%	-$1.36M	0.34%	61
2024 Q2	$1.73M	Buy	+65,643	New	+$1.82M	1.32%	24

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Paragon Capital Management (Utah)'s RPRX Position: Q1 2026 in Review

Paragon Capital Management (Utah) sold out of Royalty Pharma (RPRX) in Q1 2026, closing a stake of 44,254 shares — an estimated $1.71M sold.

Paragon Capital Management (Utah) first reported a position in RPRX in Q2 2024 and held it in 7 quarters. The position peaked at $1.85M in Q2 2025. 588 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Paragon Capital Management (Utah) reported no remaining Royalty Pharma position as of Q1 2026 after selling out during the quarter.
Paragon Capital Management (Utah) sold 44,254 Royalty Pharma shares in Q1 2026, an estimated $1.71M.
Paragon Capital Management (Utah) first reported a position in Royalty Pharma in Q2 2024 and held it in 7 quarters.
Paragon Capital Management (Utah)'s Royalty Pharma position peaked at $1.85M in Q2 2025.
588 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Paragon Capital Management (Utah)'s 13F filing for Q1 2026, filed 17 Apr 2026.